Epidemiological surveillance of the HIV/AIDS complex through the analysis of trends in the incidence of Kaposi’s sarcoma in Cali, Colombia
Abstract
Introduction: The Kaposi’s sarcoma (KS) incidence has markedly changed in the general population since the onset of the AIDS epidemic in the eighties and after the introduction of the Highly Active Antiretroviral Therapy (HAART) in the nineties.
Objective: To investigate incidence rate trends for Kaposi’s sarcoma before and during the (HIV/AIDS) epidemic in Cali, Colombia.
Methods: Exploratory ecological study that included all Kaposi’s sarcoma cases identified by the Cali Cancer Registry from 1962-2007, and 12,887 cases of HIV/AIDS recorded in the Municipal Health Secretariat of Cali between 1986 and 2010. The joinpoint regression model was used to conduct the incidence rate analyses between the years 1962 and 2010.
Results: A total of 349 KS cases were identified during the study period. Only 5.3% of the cases (n=20) were diagnosed in the pre-epidemic era (1963-1987), of these, 35.0% were women, and 90.0% of the tumors were located on the skin. In contrast, 94.7% of KS cases (n=329) were discovered after the emergence of HIV-AIDS. There was a significant decrease in the proportion of women (10.9%, p <0.001) and an increase in the frequency of tumors with an extra-cutaneous location (19.1%, p <0.01) compared to those cases diagnosed in the pre-epidemic era. Notification rates of HIV/AIDS have decreased since 2002 in both genders but KS incidence rates have decreased since 2004 in men only.
Conclusion: The downward trend in the incidence of these diseases may be associated with factors that prevent the transmission of HIV infection or limit the spread of HIV in the community. Cancer registries represent a resource for timely, population-based surveil-lance of HIV-associated malignancies in Cali, Colombia.
Authors
Downloads
Keywords
- Sarcoma de Kaposi
- VIH SIDA
- Terapia Antirretroviral
References
1. Serraino D, De Paoli A, Zucchetto A. The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies era. Cancer Epidemiol. 2010; 34(3): 257-61.
2. Safai B, Johnson KG, Myskowski PL.The natural history of Kaposi’s sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 1985; 103(5): 744-50.
3. Franceschi S, Maso LD, Rickenbach M. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer. 2008; 99(5): 800-4.
4. Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007; 19(5): 446-51.
5. Correa P, Llanos G. Morbidity and mortality from cancer in Cali, Colombia. J Nat Canc Inst. 1966; 36(4): 717.
6. Pineda CA. Guías Preventivas por ciclo vital individual en Colombia. Colomb Med. 2006;. 37(2): 65-74.
7. Stata/IC 12.0. College Station, TX 77845. USA: StataCorp LP; 2011.
8. Joinpoint Regression Program. 3.5.4 ed: Statistical Research and Applications Branch, National Cancer Institute.; August, 2012.
9. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual per cent change in trend analysis. Stat Med. 2009; 28(29): 3670-82.
10. Stebbing J, Gazzard B, Mandalia S, Teague A, Waterston A, Marvin V, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin’s lymphoma. J Clin Oncol. 2004; 22(11): 2177-83.
11. Orozco B, Gómez LM, Estrada S, Restrepo BN, Cataño JC. Relationship between human herpes virus 8 and Kaposi sarcomain HIV positive and negative patients. Infection. 2007; 11(3): 111-6.
12. Ministerio de Salud y Protección Social-ONU-SIDA Informe mundial de avances en la lucha contra el Sida. Colombia 2012. Pag 20-7
13. De Cock KM, Jaffe HW, Curran JW. The evolving epidemiology of HIV/AIDS. AIDS. 2012; 26(10): 1205-13.
14. Lunardi-Iskandar Y, Bryant JL, Zeman RA. Tumorigenesis and metastasis of neoplastic Kaposi’s sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature. 1995; 375: 64-8.
15.Lemly DC, Shepherd BE, Hulgan T. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis. 2009; 199(7): 991-8.
16. Nicastri E, Leone S, Angeletti C. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother. 2007; 60(4): 724-32.
17. Ortego C, Huedo-Medina TB, Santos P. Sex differences in adherence to highly active antiretroviral therapy: A meta-analysis. AIDS Care. 2012; 24(12): 1519-34.
18. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med. 2003; 11(2): 55-9.
19. Moreno Chaves TdC. Casos de VIH/sida en Colombia notificados al SIVIGILA, 2008. Inf Quinc Epidemiol Nac. 2009; 14(7): 97-107.
20. Clarke CA, Glaser SL. Population-based surveillance of HIV-associated cancers: utility of cancer registry data. J Acquir Immune Defic Syndr. 2004; 36(5): 1083-91.
21. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 2007; 165(10): 1143-53.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use
